Hampton Corley, Chief Business Officer of Clinipace Worldwide, a global full-service clinical research organization (CRO), has been appointed to the Board of Directors of the American Society of Nephrology’s Kidney Health Initiative (KHI). Corley will serve on the Board for a renewable three-year term from January 1, 2018, to December 31, 2020.
“I welcome this opportunity to support the efforts of the KHI,” said Corley. “Our company endorses the initiative’s mission of advancing scientific understanding of the kidney health and patient safety implications of new and existing medical products, and therapy development of therapies for kidney disease – an area of great unmet need.”
“Nephrology is a key therapeutic area for Clinipace going forward,” said Eric B. Grossman, MD, Vice President and Medical Director of Clinipace Worldwide. “We especially support the KHI’s efforts to create a collaborative environment in which sponsors, regulators, Principal Investigators and the greater nephrology community can interact to optimize evaluation of therapies.”
Clinipace will attend the KHI Open House on Friday, November 3, in New Orleans, during the ASN Kidney Week.